Abstract:Therapeutic bispecific antibodies are formed by assembly of multichain polypeptides. In general, a bispecific antibody has two different light chains and two different heavy chains that fold and correctly pair via engineered interchain interactions. Because of some incorrect assembly, product-related impurities can be prevalent (e.g., half molecules, mispaired light chains, homodimers), requiring its removal during subsequent purification. In this study, we investigated the modulation of impurity levels in a stable Chinese hamster ovary cell line X expressing a bispecific antibody A formed by two light chains (LC1 and LC2) and two heavy chains (HC1 and HC2) that assembled intracellularly into a heterodimer (LC1-HC1 + LC2-HC2) via engineered charged residues. Cell line X exhibited the best volumetric productivity, growth, and viability in culture compared with other clones but also showed higher levels of half antibody species (>10%); therefore, to minimize process yield loss, better understanding, and control of impurity formation was pursued. We found this cell line decreased half antibody levels from 16% to 1% when temperature changed from 36°C to 32.5°C or 31.5°C. However, lower temperature also increased high-molecular-weight (HMW) species from 4% to 12%. To determine the impurity species composition, we characterized enriched fractions with half antibody or HMW. Intact mass spectrometry analysis revealed half antibody was LC2-HC2, whereas HMW was a mixture with ~50% as LC1-HC1 homodimer. Results suggested LC2-HC2 was easily folded and could be secreted as half antibody, especially at 36°C. On the contrary, LC1-HC1 was more susceptible to misfold or aggregate, a phenomenon more acute for cell line X at lower culture temperature because of 60% increased LC1 and HC1 messenger RNA levels. Although temperature modulation was cell line X-specific, the propensity of LC2-HC2 to form half antibodies and LC1-HC1 to aggregate appeared in other cell lines also expressing bispecific antibody A, suggesting an amino-acid sequence-dependent mechanism. In summary, impurity formation in cell line X was temperature-dependent and was influenced by different molecule characteristics between the LC1-HC1 and LC2-HC2 parts. Ultimately, we selected a biphasic cell culture process with a growth phase followed by a lower temperature phase to improve product quality and purification yield.

Mitigating the Aggregation Challenge in Immunocytokine Production: Strategies during Cell Line Development and Purification Optimization

An innovative platform to improve asymmetric bispecific antibody assembly, purity, and expression level in stable pool and cell line development

Efficient mAb production in CHO cells with optimized signal peptide, codon, and UTR

Development of a robust and semi-automated two-step antibody purification process

Targeted CHO cell engineering approaches can reduce HCP‐related enzymatic degradation and improve mAb product quality

Improved Titer in Late-Stage Mammalian Cell Culture Manufacturing by Re-Cloning

Optimization of Heavy Chain and Light Chain Signal Peptides for High Level Expression of Therapeutic Antibodies in CHO Cells

Efficient production of bispecific antibodies-optimization of transfection strategy leads to high-level stable cell line generation of a Fabs-in-tandem immunoglobin

Efficient Development of a Stable Cell Pool for Antibody Production Using a Single Plasmid

Impact of fed-batch process intensification on the productivity and product quality of two CHO cell lines expressing unique novel molecular format proteins

Proteomic Profiling of IgG1 Producing CHO Cells Using LC/LC-SPS-MS3: The Effects of Bioprocessing Conditions on Productivity and Product Quality

Towards continuous mAb purification: Clearance of host cell proteins from CHO cell culture harvests via “flow‐through affinity chromatography” using peptide‐based adsorbents

Dynamic optimization of an integrated cultivation‐aggregation model for mAb production

Risk Control of Host Cell Proteins in One Therapeutic Antibody Produced by Concentrated Fed‐batch (CFB) Mode

Inactivation of Deubiquitinase CYLD Enhances Therapeutic Antibody Production in Chinese Hamster Ovary Cells

Two major mechanisms contributing to copurification of CHO host cell proteins and strategies to minimize their negative impact

Reduction of charge variants by CHO cell culture process optimization

Biomimetic Affinity Chromatography for Antibody Purification: Host Cell Protein Binding and Impurity Removal.

Culture temperature modulates half antibody and aggregate formation in a Chinese hamster ovary cell line expressing a bispecific antibody

Recombinant antibodies aggregation and overcoming strategies in CHO cells

Utilizing targeted integration CHO pools to potentially accelerate the GMP manufacturing of monoclonal and bispecific antibodies